Use of electronic data to raise the standard of cancer care

A new direction for development of targeted cancer therapies

Application of next generation sequencing

Next generation sequencing and WIN therapeutics

Identifying targets with systems medicine

Importance of early detection and the ‘Beyond the Shock’ programme

Shortening the timeline for clinical drug developments

Building international collaborations and the WINTHER trial

Identifying drug sensitivity and resistance in acute myeloid leukaemia

Mouse models and proteomics tackling acute lymphoblastic leukaemia

Assessing iron overload and toxicity

BRCA carrier status as a prognostic factor for prostate cancer